相关实验视频
Updated: Sep 10, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.0K
蒂卡格勒尔悖论:系统审查和网络元分析
Atsuyuki Watanabe1, Tadao Aikawa2, Yoshihisa Miyamoto3
1Department of Medicine, Mount Sinai Morningside and West Icahn School of Medicine at Mount Sinai New York NY USA.
Journal of the American Heart Association
|August 23, 2025
概括
具有里程碑意义的PLATO试验对治疗急性冠状动脉综合征的指导方针产生了重大影响,使得蒂卡格勒罗比克洛皮多格勒更受青. 然而,这项分析质疑了PLATO
科学领域:
- 心脏病学
- 药理学
- 临床试验
背景情况:
- 根据PLATO和TRITON-TIMI38试验,目前的指导方针建议在急性冠状动脉综合征治疗中使用蒂卡格勒和普拉苏格勒,而不是克洛皮多格勒.
- 随后的研究质疑了在PLATO试验中报告的蒂卡格勒罗的益处的可重现性.
研究的目的:
- 评估PLATO试验对双抗血小板治疗的综合风险估计的影响.
- 为了比较Ticagrelor,Prasugrel和Clopidogrel的网络元分析,包括和不包括PLATO数据.
主要方法:
- 随机试验的系统综述和元分析,比较阿司匹林加上克洛皮多格雷尔,普拉苏格雷尔或提卡格雷尔.
- 网络元分析包括和不包括PLATO试验数据.
- 评估结果包括主要心血管不良事件,死亡率,心肌梗塞,支架血栓和出血事件.
主要成果:
- 包括12项试验,52,415名患者.
- 包括PLATO试验在内的分析显示,在主要心血管不良事件,死亡率和心肌梗塞中,蒂卡格勒勒与克洛皮多格勒的危险比率明显较低.
- 这两种药物都与出血风险的增加有关,但当包括PLATO时,提卡格雷勒的点估计值较低.
结论:
- 由于包含了PLATO试验数据,对提卡格勒有利的统计估计得到了很大影响.
- 由于PLATO对双重抗血小板治疗的风险估计有显著影响,这些发现表明需要进一步的证据.
- 需要进一步研究以澄清这些抗血小板剂的比较有效性和安全性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
676
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
676
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
46
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
46
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22

